GUANGZHOU, China, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that all shareholder resolutions proposed at the Company’s 2023 annual general meeting held today were duly passed. Specifically, the shareholders passed the following resolutions:

Read the original here:
Burning Rock Announces Results of 2023 Annual General Meeting

Regulated Information – Inside Information

Here is the original post:
argenx Reports Topline Results from ADDRESS Study of Efgartigimod SC in Pemphigus

Ad Hoc Announcement Pursuant to Art. 53 LR

See original here:
Addex Shareholders Approve All Resolutions at Extraordinary General Meeting

Ad hoc announcement pursuant to Art. 53 LR

Excerpt from:
Basilea announces accelerated loan repayment

Read more:
Carbios praised by French President at two-year anniversary of France 2030

– Professor Dr. med. Thomas Seufferlein appointed Chair of new Scientific Advisory Board (SAB) composed of leaders with deep expertise in the clinical oncology field –

See the original post here:
Immodulon Announces Formation of New Scientific Advisory Board to Support Late-stage Clinical Development of IMM-101

BERWYN, Pa., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (AD) and Parkinson’s disease (PD) today announced its Founder, President and CEO was selected to participate in the 139th Yale CEO Summit in New York on December 11-12, 2023.

Read the original post:
Annovis Bio to Participate in the 139th Yale CEO Summit

Durable B cell aplasia up to 76 days observed in non-human primates following a single dose of VivoVec™ particles without lymphodepletion, exceeding industry benchmarks for ex vivo CAR T cell therapies

Read this article:
Umoja Biopharma Presents Preclinical Data at the 65th American Society of Hematology Annual Meeting Demonstrating In Vivo CAR T Cell Generation with...

Press Release

Read the rest here:
Mendus announces positive survival data from Phase 2 ADVANCE II trial evaluating vididencel as maintenance therapy for AML at ASH 2023

-- Positive trends continue as more patients receive treatment with WU-CART-007 in this study exploring the drug’s potential in improving standard of care-- WU-CART-007 continues to demonstrate favorable tolerability profiles in additional patients with R/R T-ALL/LBL-- Initial evidence of anti-leukemic activity and notable clinical improvement reinforced by composite complete remission rate of 60% at dose levels (DL) 2 and 3

Excerpt from:
Wugen Presents Latest Data from First-In-Human Phase 1/2 Trial of WU-CART-007 in Patients with Difficult-to-Treat Blood Cancers at American Society of...

HAYWARD, Calif., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Predicine, Inc., a leading molecular insights company, announced a significant clinical milestone with the new publication of Genentech’s Divarasib plus Cetuximab study in Nature Medicine. This study validates the clinical utility of PredicineBEACON™, a personalized minimal residual disease (MRD) liquid biopsy assay, in reinforcing Genentech's Phase 1b clinical trial of Divarasib plus Cetuximab in colorectal cancer (CRC). This study exemplifies Predicine's continued leadership in the realm of liquid biopsy technology innovation and MRD.

The rest is here:
Nature Medicine Study Validates PredicineBEACON™ MRD Liquid Biopsy Assay in Genentech’s Phase 1b Clinical Trial of Divarasib Plus Cetuximab in CRC

— Fiscal year 2023 revenue up 4.5% to $572.4 million, achieving full year revised guidance— Achievements in the past fiscal year to expand DSA capacity, develop new services and reduce outsourcing expected to drive continued growth of fiscal 2024 DSA revenues— Anticipate achieving the balance of expected expense reductions in fiscal 2024— Conference call begins today at 4:30 pm ET

Visit link:
Inotiv Reports Fourth Quarter and Full Year Financial Results for Fiscal 2023 and Provides Business Update

– Complete remission seen in 42% of patients with CBF/GLIS AML with ?5% blasts and 75% of pediatric patients with CBF/GLIS AML with <5% blasts; treatment with luvelta was either alone or in combination –

Read the original post:
Sutro Biopharma Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin (luvelta) in Pediatric Patients with...

NEW YORK, Dec. 11, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced positive updated data from its Phase 1 investigator-sponsored trial of INB-100 in patients with hematologic malignancies. The data, which will be presented in a poster presentation at the 65th ASH Annual Meeting & Exposition this evening, demonstrated that 100% of evaluable leukemia patients (n=10) treated remained alive, progression-free, and in durable complete remission (CR) as of November 3, 2023. The Company believes this data indicate the curative potential of INB-100 to provide durable relapse free periods for high-risk or relapsed AML and other hematologic malignancies undergoing hematopoietic stem cell transplantation (HSCT). The CRs to date, combined with INB-100’s benefit/risk profile are encouraging for the treatment of hematological malignancies and the trial is being expanded by ten patients at Dose Level (DL) 2, the recommended Phase 2 dose (RP2D). Additional expansion patient enrollment is on-going and updated data is expected to be presented at medical meetings in 2024.

See the article here:
IN8bio Announces Positive Clinical Update Demonstrating Continued Durable Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100...

Data from Study Anticipated in Q1 2024 Data from Study Anticipated in Q1 2024

Link:
Third Pole Therapeutics Announces First Patient Dosed in Feasibility Study with eNOfit™ Portable Inhaled Nitric Oxide Delivery System

SAN DIEGO, CA and TAICANG, China, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today announced that it will present top-line data from the global Phase 2b trial evaluating rademikibart’s efficacy and safety in patients with moderate-to-severe asthma on Tuesday, December 12, 2023, prior to market open. Following the announcement, the Company will host a conference call and webcast presentation at 8:30 a.m. ET to discuss the top-line data. The call will feature a discussion with Dr. Edward M. Kerwin, MD, Founder and Senior Medical Director of the Clinical Research Institute, Allergy and Asthma Center and Altitude Clinical Consulting.

See the original post here:
Connect Biopharma to Announce Top-Line Data from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma on December 12,...

Read the original here:
Press Release: Statement on FTC challenge to proposed license agreement with Maze Therapeutics

SEATTLE and VANCOUVER, British Columbia, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that Achieve management will be participating in the following upcoming investor conferences.

Here is the original post:
Achieve Life Sciences Announces Participation at Upcoming Investor Conferences

Minimal residual disease negativity (MRD-) observed in all treated patients in the ongoing study, with 95% (21/22) achieving stringent complete response (sCR) through a median follow-up of 18.8 months

Read the original:
Gracell Biotechnologies Presents Updated Clinical Data from FasTCAR-T GC012F Demonstrating Deep and Durable Responses in Newly Diagnosed Multiple...

• HPN217 was well tolerated and demonstrated robust and durable clinical activity at doses ranging from 2.15 to 24 mg in heavily pre-treated patients, including patients with prior exposure to BCMA-targeted therapy

Go here to see the original:
Harpoon Therapeutics Presents HPN217 Phase 1 Clinical Data in Relapsed/Refractory Multiple Myeloma (RRMM) at ASH 2023 and Announces Selection of...